Reaction
Lipids Increased reporting signals
As of the last recalculation, Lipids Increased appears in 1,979 FAERS reports alongside 35 co-occurring drug terms. The strongest observed disproportionality signal is INCLISIRAN (PRR 25.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Inclisiran | 19 | 25.1 | 25.2 |
| Ritonavir 100 Mg | 23 | 16.4 | 16.4 |
| Efavirenz | 16 | 15.2 | 15.2 |
| Baricitinib | 13 | 14.3 | 14.3 |
| Gemfibrozil | 20 | 14.0 | 14.0 |
| Isotretinoin | 62 | 13.6 | 13.6 |
| Upadacitinib | 93 | 12.5 | 12.6 |
| Olanzapine Pamoate | 44 | 11.5 | 11.6 |
| Ritonavir | 31 | 11.3 | 11.3 |
| Darunavir | 16 | 11.2 | 11.2 |
| Lopinavir And Ritonavir | 14 | 10.9 | 10.9 |
| Niacin | 12 | 10.9 | 10.9 |
| Amitriptyline Hydrochloride | 16 | 9.7 | 9.7 |
| Sirolimus | 12 | 9.4 | 9.4 |
| Tofacitinib | 140 | 8.5 | 8.5 |
| Daspone | 7 | 7.6 | 7.6 |
| Dapsone Gel, 5% | 7 | 7.6 | 7.6 |
| Zidovudine | 9 | 7.1 | 7.1 |
| Raltegravir | 11 | 7.0 | 7.0 |
| Dolutegravir Sodium | 6 | 7.0 | 7.0 |
| Nilotinib | 19 | 6.8 | 6.8 |
| Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate | 11 | 6.4 | 6.4 |
| Alirocumab | 15 | 6.3 | 6.3 |
| Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide | 6 | 6.3 | 6.3 |
| Tocilizumab | 63 | 6.0 | 6.0 |
| Ziprasidone Mesylate | 7 | 5.2 | 5.2 |
| Tenofovir Disoproxil Fumarate Tablets | 4 | 4.9 | 4.9 |
| Ixekizumab | 17 | 4.9 | 4.9 |
| Evolocumab | 71 | 4.7 | 4.7 |
| Emtricitabine And Tenofovir Alafenamide | 5 | 4.6 | 4.6 |
| Apalutamide | 5 | 4.5 | 4.5 |
| Paliperidone | 9 | 4.1 | 4.1 |
| Paliperidone Palmitate | 9 | 3.0 | 3.0 |
| Sarilumab | 6 | 2.4 | 2.4 |
| Dulaglutide | 15 | 1.8 | 1.8 |